Hamilton Lenox Joins LGM Pharma as Senior VP of Business Development

Hamilton Lenox Joins LGM Pharma as Senior VP of Business Development

Hamilton Lenox Joins LGM Pharma as Senior VP of Business Development
LGM Pharma, Press Release

ERLANGER, Kentucky / BOCA RATON, Florida — LGM Pharma, an innovation-driven active pharmaceutical ingredient (API) company, headquartered in Erlanger, Kentucky with offices in Florida, New Jersey and Israel recently announced the appointment of Hamilton J. Lenox as Senior Vice President of Business Development at the Boca Raton, Florida location. In this capacity, Mr. Lenox will be responsible for leading LGM’s drug development unit’s sales, business development and marketing team.

Mr. Lenox has more than 17 years’ experience in drug development, having represented CDMOs in the US, Europe, China and India, and he brings significant expertise and experience in the small molecule, biologic, peptide, oligonucleotide and personalized vaccine drug development markets to LGM. He most recently led CPC Scientific’s East Coast business development team, strengthening their clinical and commercial stage peptide therapeutic pipeline while also helping develop their new service offering supporting peptide based neoantigen programs. Prior to that he directed small molecule and oligonucleotide business development efforts at Nitto Denko Avecia, revitalizing their struggling small molecule facility while also increasing Avecia’s oligonucleotide pipeline for the East Coast and Asian markets. He holds a BS in Chemistry from DePaul University, a MS in Biochemistry from Northwestern University and an MBA from Florida International University.

According to Mendy Schurder, COO for LGM, “We are excited to have Hamilton as part of the team. He has a proven record of facilitating long-term business relationships with both customers and industry luminaries. His extensive experience assisting biotech and pharma organizations during the drug development lifecycle, combined with his strong network, are assets that will complement and enhance LGM’s ability to meet the needs of our customers as we continue to provide quality, innovative products to the marketplace.”

About LGM Pharma

LGM Pharma is an innovation-driven organization and a recognized global leader in sourcing and distribution of quality CGMP APIs to leading pharmaceutical & biotech companies. LGM specializes in streamlining API supply chain management throughout R&D, clinical and commercial stages, ensuring technical competence and adherence to timelines / specifications from suppliers while also providing expert guidance to navigate complex global regulatory submission strategies.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service